title: Efficacy of carbamazepine compared with other agents: a clinical practice survey.
abstract: BACKGROUND
  To gain an impression of the experience with and efficacy of carbamazepine relative to other agents and relative to its use in treating psychiatric and neurologic disorders in general clinical practice, a survey was distributed in 1988 to psychiatrists practicing in the United States.
  
  
  METHODS
  The survey was mailed to 9030 members of the American Psychiatric Association (APA) who had expressed an interest in the study and treatment of affective disorders in a 1982 APA survey. The survey sampled clinicians' experience of the efficacy and side effects of carbamazepine in a number of psychiatric and neurologic conditions. Each clinician also provided global impression ratings of the efficacy of a variety of traditional and novel treatments.
  
  
  RESULTS
  Completed surveys were returned by 2543 (28%) physicians. Carbamazepine was reported to be moderately to markedly effective in the following percentage of patients: partial complex seizures, 85.2%; generalized seizures, 82.9%; trigeminal neuralgia, 81.5%; mania prophylaxis, 72.9%; acute bipolar depression, 67.5%; intermittent explosive disorder, 65.2%; acute mania, 62.2%; schizoaffective disorder, 58.8%; other pain syndromes, 51.2%; posttraumatic stress disorder, 48.1%; borderline personality disorder, 43.0%; unipolar depression, 32.2%; schizophrenia, 25.7%; and alcohol withdrawal, 15.9%. About 4.4% of the patients reported were withdrawn from carbamazepine because of side effects.
  
  
  CONCLUSIONS
  Carbamazepine was widely used to treat a variety of psychiatric conditions in 1988 and found to be of use in the acute and long-term treatment of bipolar illness. It was rated slightly less effective than lithium, electroconvulsive therapy, or neuroleptics, but more effective than several other agents. The results of the survey highlight many areas in need of further systematic investigation.
authors.affiliation: Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 20892.
authors.forename: K D
authors.initials: KD
authors.lastname: Denicoff
authors.forename: S B
authors.initials: SB
authors.lastname: Meglathery
authors.forename: R M
authors.initials: RM
authors.lastname: Post
authors.forename: S I
authors.initials: SI
authors.lastname: Tandeciarz
mesh_terms: D001291:Attitude of Health Personnel; D001714:Bipolar Disorder / Q000188:drug therapy / Q000517:prevention & control; D002220:Carbamazepine / Q000008:administration & dosage / Q000627:therapeutic use*; D004363:Drug Utilization; D004565:Electroconvulsive Therapy; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy* / Q000517:prevention & control; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000517:prevention & control; D010146:Pain / Q000188:drug therapy / Q000517:prevention & control; D010818:Practice Patterns, Physicians'; D011570:Psychiatry; D012640:Seizures / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D002220:Carbamazepine; D008094:Lithium